Mirum Pharmaceuticals (MIRM) Stock Analysis & AI Equity Report
Mirum Pharmaceuticals (MIRM) overview
Mirum Pharmaceuticals (MIRM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 521m and operating profit of USD -22.1m; the year-end share price was 78.99 USD and market capitalisation was USD 4,099m. Mirum Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Mirum Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Mirum Pharmaceuticals
Mirum Pharmaceuticals develops and commercializes medicines for rare diseases. Its commercial portfolio includes Livmarli for Alagille syndrome and progressive familial intrahepatic cholestasis; ATEBRIOZ for fibrodysplasia ossificans progressiva; and Cholbam and Ctexli for specified bile-acid disorders. Its pipeline includes volixibat for cholestatic liver diseases, brelovitug for chronic hepatitis delta, and MRM-3379 for fragile X syndrome.
Generate the Mirum Pharmaceuticals report
Mirum Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Mirum Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Mirum Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.